Apellis Pharmaceuticals/APLS

$48.00

-0.06%
-
1D1W1MYTD1YMAX

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). Its EMPAVELI (pegcetacoplan), is for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) for the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. Systemic pegcetacoplan has also been approved for the treatment of PNH in Japan, Saudi Arabia, Australia, the United Kingdom and other jurisdictions. Systemic pegcetacoplan is marketed under the trade name EMPAVELI in the United States, Saudi Arabia and Australia and Aspaveli in the European Union, Japan and United Kingdom.

Ticker

APLS

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Cedric Francois

Employees

702

Headquarters

Waltham, United States

APLS Metrics

BasicAdvanced
$6.21B
Market cap
-
P/E ratio
-$4.48
EPS
0.92
Beta
-
Dividend rate
$6.21B
0.92369
$94.75
$19.83
1.38M
3.095
2.504
171.113
210.096
-59.78%
-68.26%
-290.14%
-93.25%
15.658
31.653
31.924
425.83%
26.94%
16.53%

What the Analysts think about APLS

Analyst Ratings

Majority rating from 17 analysts.
Buy

Price Targets

Average projection from 15 analysts.
71.1% upside
High $110.00
Low $57.00
$48.00
Current price
$82.13
Average price target

APLS Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-60.49% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$146.3M
32.64%
Net income
$-88.5M
-36.88%
Profit margin
-60.49%
-52.41%

APLS Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 6.36%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$1.56
-$1.02
-$1.17
-$0.73
-
Expected
-$1.46
-$1.32
-$0.86
-$0.69
-$0.55
Surprise
6.55%
-22.89%
36.77%
6.36%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Apellis Pharmaceuticals stock?

Apellis Pharmaceuticals (APLS) has a market cap of $6.21B as of April 18, 2024.

What is the P/E ratio for Apellis Pharmaceuticals stock?

The price to earnings (P/E) ratio for Apellis Pharmaceuticals (APLS) stock is 0 as of April 18, 2024.

Does Apellis Pharmaceuticals stock pay dividends?

No, Apellis Pharmaceuticals (APLS) stock does not pay dividends to its shareholders as of April 18, 2024.

When is the next Apellis Pharmaceuticals dividend payment date?

Apellis Pharmaceuticals (APLS) stock does not pay dividends to its shareholders.

What is the beta indicator for Apellis Pharmaceuticals?

Apellis Pharmaceuticals (APLS) has a beta rating of 0.92. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Apellis Pharmaceuticals stock price target?

The target price for Apellis Pharmaceuticals (APLS) stock is $82.13, which is 71.1% above the current price of $48. This is an average based on projections from 15 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Apellis Pharmaceuticals stock

Buy or sell Apellis Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing